We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
UK-based biotechnology venture Cambridge Antibody Technology (CAT)
has reported results for the first quarter of its financial year, for October
through the end of December 2004.
Indian drug producer Zydus Cadila has filed its first investigational
new drug application for a new compound to treat metabolic disorder, following
completion of preclinical studies.
Indian drugmaker Dr. Reddy's has begun Phase I clinical trials for
a new compound, known as RUS 3108, to treat atherosclerosis, a significant cause
of cardiovascular events such as heart attack and stroke.
Japanese drug major Takeda has announced that it will acquire US
biotechnology firm Syrrx for US$270mn, as the company attempts to expand its
pipeline.
Health sector leaders in Brazil have criticised the government's
plans to further centralise state drug provision in the hands of the federal
Health Ministry.
Two drug majors, the UK's GlaxoSmithKline (GSK) and US-based Merck
& Co., have agreed a royalties deal on a vaccine for the human papillomavirus,
the leading cause of cervical cancer.
Leading Indonesian drug producer PT Kalbe Farma has recorded interim
net profit of IDR377bn (US$41.02mn) for 2004, a 17 percent increase on the company's
full-year 2003 result.